Article
COVID-19 After Treatment With Direct-acting Antivirals for HCV Infection and Decompensated Cirrhosis: A Case Report.
In vivo (Athens, Greece) - 1 Jan 2000
Ikegami Chikako, Kanda Tatsuo, Ishii Tomotaka, Honda Masayuki, Yamana Yoichiro, Tanaka Reina Sasaki, Kumagawa Mariko, Kanezawa Shini, Mizutani Taku, Yamagami Hiroaki, Matsumoto Naoki, Masuzaki Ryota, Hayashi Kentaro, Nirei Kazushige, Takayama Tadateru, Moriyama Mitsuhiko
Abstract excerpt
BACKGROUND: Eradication of hepatitis C virus (HCV) from chronic HCV-infected patients could improve liver function and prevent hepatocarcinogenesis in the long term. Eradication of HCV by direct-acting antivirals (DAAs) also leads to dynamic immunological changes. We report a case of recurrent coronavirus disease 2019 (COVID-19) that developed immediately after combination treatment with DAAs for HCV infection...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.